Evaluation pharmaco-épidémiologique de la combinaison thérapeutique recommandée en prévention secondaire cardiovasculaire

Evaluation pharmaco-épidémiologique de la combinaison thérapeutique recommandée en prévention secondaire cardiovasculaire

En France, le syndrome coronaire aigu (SCA) représente environ 100 000 hospitalisations par an. Il est recommandé, en prévention secondaire du SCA, un traitement combinant quatre classes médicamenteuses : bêtabloquants, antiagrégants plaquettaires, statines, et inhibiteurs de l’enzyme de conversion...

Full description

Bibliographic Details
Main Author:	Bezin, Julien
Other Authors:	Bordeaux
Language:	fr
Published:	2016
Subjects:	Pharmaco-épidémiologie Syndrome coronaire aigu Prévention secondaire Bêtabloquant Antiagrégant plaquettaire Statine Inhibiteur de l’enzyme de conversion Antagoniste des récepteurs à l’angiotensine II Pharmacoepidemiology Beta-blockers Antiplatelet agents Statins Angiotensin converting enzyme inhibitors Angiotensin receptor blockers Acute coronary syndrome Secondary prevention
Online Access:	http://www.theses.fr/2016BORD0320/document

Similar Items

Blocking angiotensin earlier with RAS blockers, statins, and heparin in high-risk COVID-19 patients: Is the remedy here?
by: Imdat Eroğlu, et al.
Published: (2020-07-01)

Contrôle pharmacologique de l'apoptose cardiovasculaire dans l'hypertension : implication de la voie de l'angiotensine et de la correction de la dysfonction endothéliale
by: Der Sarkissian, Shant
Published: (2016)

Acute coronary syndrome: pathogenesis, diagnosis, treatment, rehabilitation (Lecture 3)
by: N. B Perepech
Published: (2016-12-01)

Reply to Siniorakis et al., “COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure”
by: David S. Fedson, et al.
Published: (2020-05-01)

Impact of drug therapy on the risk of death in patients with coronary heart disease (according to the data of registry of cardiovascular diseases, RECVASA)
by: K. G Pereverzeva, et al.
Published: (2017-09-01)

A real way of reducing coronary heart disease mortality in Russia
by: D. M Aronov, et al.
Published: (2010-03-01)

Concomitant use of renin-angiotensin-aldosterone system inhibitors prevent trastuzumab-induced cardiotoxicity in HER2+ breast cancer patients: an institutional retrospective study
by: Melissa Y. Y. Moey, et al.
Published: (2019-07-01)

Effect of Different Classes of Antihypertensive Drugs on Endothelial Function and Inflammation
by: Isabella Viana Gomes Silva, et al.
Published: (2019-07-01)

The problem of determining the efficiency of treatmentin the era of evidence-based medicine: international and domestic experience
by: S R Gilyarevsky
Published: (2014-06-01)

Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study
by: Jenny I. Shen, et al.
Published: (2017-06-01)

Nouveaux ligands du récepteur B₂ de la bradykinine : endocytose dirigée et catabolisme sélectif
by: Roy, Caroline
Published: (2013)

Usage des IECA / ARA II chez des aînés traités contre le diabète de type 2
by: Hamdi, Haithem
Published: (2011)

Angiotensin II Promotes SARS-CoV-2 Infection via Upregulation of ACE2 in Human Bronchial Cells
by: Brini, M., et al.
Published: (2022)

Angiotensins and rheumatoid arthritis
by: N. M. Savushkina, et al.
Published: (2019-01-01)

Protection against oxidative DNA damage by antioxidants, hormone-receptor blockers and HMG-CoA-reductase inhibitors
by: Schmid, Ursula
Published: (2008)

2019 novel-coronavirus: Cardiovascular insights about risk factors, myocardial injury, therapy and clinical implications
by: Luigi Cappannoli, et al.
Published: (2020-12-01)

COVID-19 morbidity and mortality associated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers use among 14,129 patients with hypertension from a US integrated healthcare system
by: Jaejin An, et al.
Published: (2021-06-01)

Resistance to antihypertensive drugs targeting Renin-Angiotensin-Aldosterone-System in cancer patients: a case series
by: Mishita Goel, et al.
Published: (2020-08-01)

Angiotensin-converting enzyme inhibitors or sartans in patients at high risk for cardiovascular events: a wrong question or an undesirable answer
by: S R Gilyarevsky, et al.
Published: (2013-03-01)

Skin Reactions with Losartan and Enalapril in Cardiac Patients
by: Fariba Iraji, et al.
Published: (2012-03-01)

TO THE 110-TH ANNIVERSARY OF RENIN FINDING. FIGHT OF TITANS: ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND SARTANS
by: L. N. Malay, et al.
Published: (2016-01-01)

ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS: IS THERE A REASON TO CONSIDER AN EQUIVALENCE OF TWO DRUG CLASSES FROM THE EVIDENCE BASED MEDICINE STANDPOINT
by: S. Yu. Martsevich
Published: (2015-09-01)

Associations between Pharmacotherapy for Cardiovascular Diseases and Periodontitis
by: Ewa Pająk-Łysek, et al.
Published: (2021-01-01)

A high sodium intake reduces antiproteinuric response to renin–angiotensin–aldosterone system blockade in kidney transplant recipients
by: Elena Monfá, et al.
Published: (2016-09-01)

Angiotensin-Converting Enzyme Inhibitor / Angiotensin II Receptor Blocker in COVID-19: a Double-edged Sword or a Myth
by: Kunal Bikram Shaha, et al.
Published: (2020-05-01)

Clinical outcome of renin-angiotensin-aldosterone system blockers in treatment of hypertensive patients with COVID-19: a systematic review and meta-analysis
by: Andrea Laurentius, et al.
Published: (2021-02-01)

Inhibition of Angiotensin Converting Enzyme Impairs Anti-staphylococcal Immune Function in a Preclinical Model of Implant Infection
by: Rishi Trikha, et al.
Published: (2020-09-01)

Hyponatremia Induced by Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers-A Pilot Study
by: S Bhuvaneshwari, et al.
Published: (2018-07-01)

ACE inhibitor angioedema: characterization and treatment versus non-ACE angioedema in acute hospitalized patients
by: David S. Weisman, et al.
Published: (2020-01-01)

Group-Based Trajectory Modeling to Identify Patterns of Adherence and Its Predictors Among Older Adults on Angiotensin-Converting Enzyme Inhibitors (ACEIs)/Angiotensin Receptor Blockers (ARBs)
by: Paranjpe R, et al.
Published: (2020-10-01)

Hyperkalemia Associated with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blockers in Chronic Kidney Disease
by: Yudi Her Oktaviono, et al.
Published: (2020-04-01)

Drug-induced visceral angioedema
by: Prashanth M. Thalanayar, et al.
Published: (2014-09-01)

Angiotensin receptor blockers in heart failure after the ELITE II trial
by: Willenheimer Ronnie
Published: (2000-09-01)

Relating angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers with incidence or mortality of COVID‐19
by: Martin C.S. Wong, et al.
Published: (2020-10-01)

Controversial Roles of the Renin Angiotensin System and Its Modulators During the COVID-19 Pandemic
by: Simon B. Gressens, et al.
Published: (2021-02-01)

Renin-angiotensin system blockers and COVID-19
by: Emmanuelle Vidal-Petiot, et al.
Published: (2021-06-01)

Treating Ebola patients: a ‘bottom up’ approach using generic statins and angiotensin receptor blockers
by: David S. Fedson, et al.
Published: (2015-07-01)

Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19
by: Naci Şenkal, et al.
Published: (2020-07-01)

Perspectives of using angiotensin receptor antagonists
by: V V Fomin
Published: (2009-06-01)

The use of angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers and cognitive decline in Alzheimer’s disease: the importance of blood-brain barrier penetration and APOE ε4 carrier status
by: Michael Ouk, et al.
Published: (2021-02-01)